INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

TARSTarsus Pharmaceuticals, Inc.

CIK 0001819790

EDGAR filingsOpen in network
Disclosed transactions42
Buys / sells0 / 31
Max Insider Score46
Connections10with evidence

TARS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
35
LY
Lin Elizabeth YeuChief Medical Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$485K
5,386 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Lobbied forevidence
    FORBES-TATELDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Goldberg Andrew D.Director · Jun 29, 2026
  • ← Insider ofevidence
    Wahl BryanGeneral Counsel · Mar 19, 2026
28
LY
Lin Elizabeth YeuChief Medical Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL
$135K
1,590 sh
Sep 4, 2026
Sep 9, 2026
traded Sep 4, 2026
+5d
SEC FORM 4

Evidence

20
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$265K
2,900 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

20
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$641K
7,100 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

32
LY
Lin Elizabeth YeuChief Medical Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$143K
1,590 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

31
LY
Lin Elizabeth YeuChief Medical Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$458K
5,387 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

27
NS
Neervannan SeshadriChief Operating Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$388K
4,564 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

9
GD
Goldberg Andrew D.Director
TARSTarsus Pharmaceuticals, Inc.
Grant or award
A—
3,837 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

5
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Grant or award
A—
2,417 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
GD
Goldberg Andrew D.Director
TARSTarsus Pharmaceuticals, Inc.
Grant or award
A—
2,417 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

5
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Grant or award
A—
3,837 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

18
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$335K
5,418 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

18
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$281K
4,582 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

25
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$183K
2,954 sh
Jun 15, 2026Jun 17, 2026
traded Jun 15, 2026
+2dSEC FORM 4

Evidence

21
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,954 sh
Jun 12, 2026Jun 16, 2026
traded Jun 12, 2026
+4dSEC FORM 4

Evidence

9
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,954 sh
Jun 12, 2026Jun 16, 2026
traded Jun 12, 2026
+4dSEC FORM 4

Evidence

46
WB
Wahl BryanGeneral Counsel
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$284K
4,084 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

42
WB
Wahl BryanGeneral Counsel
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$283K
4,125 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

42
WB
Wahl BryanGeneral Counsel
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$283K
4,231 sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

42
WC
Whitfield Dianne C.Chief Human Resources Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$280K
4,029 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

42
WC
Whitfield Dianne C.Chief Human Resources Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$280K
4,071 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

42
WC
Whitfield Dianne C.Chief Human Resources Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$280K
4,174 sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

39
NS
Neervannan SeshadriChief Operating Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$217K
3,125 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

42
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$762K
11.0K sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

46
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$802K
11.7K sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

46
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$802K
12.0K sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

35
NS
Neervannan SeshadriChief Operating Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$248K
3,610 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

42
NS
Neervannan SeshadriChief Operating Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$307K
4,589 sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

46
MA
Mottiwala AzizChief Commercial Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$298K
4,286 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

42
MA
Mottiwala AzizChief Commercial Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$298K
4,330 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

42
MA
Mottiwala AzizChief Commercial Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$297K
4,440 sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

36
LY
Lin Elizabeth YeuChief Medical Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$26K
375 sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

32
LY
Lin Elizabeth YeuChief Medical Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$26K
379 sh
Mar 18, 2026Mar 19, 2026
traded Mar 18, 2026
+1dSEC FORM 4

Evidence

32
LY
Lin Elizabeth YeuChief Medical Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale
SELL$26K
390 sh
Mar 19, 2026Mar 19, 2026
traded Mar 19, 2026
+0dSEC FORM 4

Evidence

31
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,233 sh
Dec 15, 2025Jan 14, 2026
traded Dec 15, 2025
+30dSEC FORM 4

Evidence

19
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,233 sh
Dec 15, 2025Jan 14, 2026
traded Dec 15, 2025
+30dSEC FORM 4

Evidence

16
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$47K
557 sh
Dec 24, 2025Dec 30, 2025
traded Dec 24, 2025
+6dSEC FORM 4

Evidence

22
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$449K
5,443 sh
Dec 24, 2025Dec 30, 2025
traded Dec 24, 2025
+6dSEC FORM 4

Evidence

12
NS
Neervannan SeshadriChief Operating Officer
TARSTarsus Pharmaceuticals, Inc.
Gift
G—
950 sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

20
WC
Whitfield Dianne C.Chief Human Resources Officer
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$592K
7,397 sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

12
NS
Neervannan SeshadriChief Operating Officer
TARSTarsus Pharmaceuticals, Inc.
Gift
G—
475 sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

12
AR
Azamian Bobak R.Director, President/CEO and Board Chair
TARSTarsus Pharmaceuticals, Inc.
Gift
G—
51.9K sh
Dec 4, 2025Dec 8, 2025
traded Dec 4, 2025
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Mottiwala AzizChief Commercial Officer · Mar 19, 2026
  • ← Insider ofevidence
    Lin Elizabeth YeuChief Medical Officer · Mar 19, 2026
  • ← Insider ofevidence
    Goodrich KatherineDirector · Jan 14, 2026
  • ← Insider ofevidence
    Whitfield Dianne C.Chief Human Resources Officer · Dec 18, 2025
  • ← Insider ofevidence
    Neervannan SeshadriChief Operating Officer · Dec 18, 2025
  • ← Insider ofevidence
    Azamian Bobak R.Director, President/CEO and Board Chair · Dec 8, 2025

    • Lobbying

    $100K reported · de-duplicated
    2026 Q2 $50K via firms2026 Q1 $50K via firms
    • FORBES-TATE$50K2026 Q2 · posted Aug 26, 2026 · Health issues
    • FORBES-TATE$50K2026 Q1 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.